PI3K/AKT/mTOR信号通路抑制剂在卵巢癌治疗中的研究进展

被引：28

作者：

陈颖

毕芳芳

杨清

机构：

[1] 中国医科大学附属盛京医院妇产科

来源：

现代药物与临床 | 2018年 / 33卷 / 05期

关键词：

PI3K/AKT/mTOR信号通路; 抑制剂; 卵巢癌; 靶向治疗;

D O I：

暂无

中图分类号：

R737.31 [卵巢肿瘤];

学科分类号：

100214 [肿瘤学];

摘要：

卵巢癌是女性生殖系统最致命的恶性肿瘤。目前,针对卵巢癌的规范治疗方案是肿瘤细胞减灭术辅以紫杉醇/铂类联合化疗,然而大多数晚期卵巢癌患者最终因对化疗药物耐药而复发。PI3K/AKT/m TOR信号通路作为一条重要的原癌基因通路,在卵巢癌中激活并在卵巢癌的增殖、侵袭、细胞周期进程、血管形成及耐药中发挥着重要的作用,抑制该通路是卵巢癌的一个潜在治疗方法。对PI3K/AKT/m TOR信号通路抑制剂在卵巢癌治疗中的研究进展进行综述。

引用

页码：1273 / 1277

页数：5

共 30 条

[1]

A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer [J].

Wainberg, Zev A. ;

Alsina, Maria ;

Soares, Heloisa P. ;

Brana, Irene ;

Britten, Carolyn D. ;

Del Conte, Gianluca ;

Ezeh, Patrick ;

Houk, Brett ;

Kern, Kenneth A. ;

Leong, Stephen ;

Pathan, Nuzhat ;

Pierce, Kristen J. ;

Siu, Lillian L. ;

Vermette, Jennifer ;

Tabernero, Josep .

TARGETED ONCOLOGY, 2017, 12 (06) :775-785

[2]

Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.[J].Hye Sook Chon;Sokbom Kang;Jae K. Lee;Sachin M. Apte;Mian M. Shahzad;Irene Williams-Elson;Robert M. Wenham.BMC Cancer.2017, 1

[3]

Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations [J].

Hasegawa, Kosei ;

Kagabu, Masahiro ;

Mizuno, Mika ;

Oda, Katsutoshi ;

Aoki, Daisuke ;

Mabuchi, Seiji ;

Kamiura, Shoji ;

Yamaguchi, Satoshi ;

Aoki, Yoichi ;

Saito, Toshiaki ;

Yunokawa, Mayu ;

Takehara, Kazuhiro ;

Okamoto, Aikou ;

Ochiai, Kazunori ;

Kimura, Tadashi .

INVESTIGATIONAL NEW DRUGS, 2017, 35 (06) :800-812

[4]

Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers [J].

Colon-Otero, Gerardo ;

Weroha, S. John ;

Foster, Nathan R. ;

Haluska, Paul ;

Hou, Xiaonan ;

Wahner-Hendrickson, Andrea E. ;

Jatoi, Aminah ;

Block, Matthew S. ;

Dinh, Tri A. ;

Robertson, Matthew W. ;

Copland, John A. .

GYNECOLOGIC ONCOLOGY, 2017, 146 (01) :64-68

[5]

A Review of mTOR Pathway Inhibitors in Gynecologic Cancer.[J].Andréia Cristina de Melo;Eduardo Paulino;álvaro Henrique Ingles Garces;Yasuhiro Maejima.Oxidative Medicine and Cellular Longevity.2017,

[6]

mTOR Signaling in Growth; Metabolism; and Disease.[J].Robert A. Saxton;David M. Sabatini.Cell.2017, 2

[7]

Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer [J].

Matulonis, U. A. ;

Wulf, G. M. ;

Barry, W. T. ;

Birrer, M. ;

Westin, S. N. ;

Farooq, S. ;

Bell-McGuinn, K. M. ;

Obermayer, E. ;

Whalen, C. ;

Spagnoletti, T. ;

Luo, W. ;

Liu, H. ;

Hok, R. C. ;

Aghajanian, C. ;

Solit, D. B. ;

Mills, G. B. ;

Taylor, B. S. ;

Won, H. ;

Berger, M. F. ;

Palakurthi, S. ;

Liu, J. ;

Cantley, L. C. ;

Winer, E. .

ANNALS OF ONCOLOGY, 2017, 28 (03) :512-518

[8]

Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes [J].

Wang, Dong ;

Li, Chengbo ;

Zhang, Yuan ;

Wang, Min ;

Jiang, Nan ;

Xiang, Lin ;

Li, Ting ;

Roberts, Thomas M. ;

Zhao, Jean J. ;

Cheng, Hailing ;

Liu, Pixu .

GYNECOLOGIC ONCOLOGY, 2016, 142 (03) :548-556

[9]

Effect of the BRCA1-SIRT1-EGFR axis on cisplatin sensitivity in ovarian cancer [J].

Li, Da ;

Wu, Qi-Jun ;

Bi, Fang-Fang ;

Chen, Si-Lei ;

Zhou, Yi-Ming ;

Zhao, Yue ;

Yang, Qing .

AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2016, 8 (03) :1601-1608

[10]

Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination [J].

Yu, Jason S. L. ;

Cui, Wei .

DEVELOPMENT, 2016, 143 (17) :3050-3060

← 1 2 3 →